<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978962</url>
  </required_header>
  <id_info>
    <org_study_id>RE-DT04-18A</org_study_id>
    <secondary_id>2018-A03202-53</secondary_id>
    <nct_id>NCT03978962</nct_id>
  </id_info>
  <brief_title>Performance and Safety of the Resorbable Collagen Membrane &quot;Ez Cure&quot;</brief_title>
  <official_title>Performance and Safety of the Resorbable Collagen Membrane &quot;Ez Cure&quot; in Guided Tissue Regeneration and Guided Bone Regeneration Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomatlante</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ATLANSTAT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomatlante</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The evaluation of the clinical data has demonstrated the conformity of the Resorbable
      Collagen Membrane (RCM), EZ CureTM, with the relevant essential requirements for its use in
      periodontal applications. The RCM is intended for Guided Tissue Regeneration (GTR) and Guided
      Bone Regeneration (GBR) procedures. It acts as a barrier against the migration of epithelial
      cells within the bone defect (performance) and thus complies with several surgical
      indications in the treatment of maxillofacial bone defects. It has been concluded that the
      risks associated with the use of this device are acceptable when weighted against the
      benefits to the patients.

      In order to improve the clinical data on the RCM, the manufacturer, Biomatlante, decided to
      assess that the performance and safety of the device are maintained until the reaching of its
      intended use. In this objective, the goal of this study will be to observe the following
      parameters:

        1. Tissue regeneration (mucosa health on the site of implantation)

        2. Safety (report of any adverse event)

        3. Radiographic analysis of periodontal tissues
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">March 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the patient's mucosa health in terms of swelling, wound closure and colour of the implantation site (visual inspection)</measure>
    <time_frame>1 week post-surgery (+/-2 days) / 2 weeks post-surgery (+/-2 days) / 12 weeks post-surgery (+/-1 week)</time_frame>
    <description>Observation of the change of the mucosa health in terms of swelling, wound closure and colour of the implantation site. It reflects the performance of the Resorbable Collagen Membrane</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and precise description of any adverse event during the follow-up</measure>
    <time_frame>From screening visit through visit at 12 weeks</time_frame>
    <description>Record and description of any adverse event during the follow-up that reflects the safety of the Resorbable Collagen Membrane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of bone reconstruction in the treated bone defect by a radiographic examination</measure>
    <time_frame>Before surgery and 12 weeks post-surgery (+/-1 week)</time_frame>
    <description>Comparison of the radiographies recorded before surgery and at the last follow-up visit</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Oral Bone Defect</condition>
  <condition>Maxillofacial Bone Defect</condition>
  <condition>Periodontal Bone Loss</condition>
  <condition>Alveolar Bone Loss</condition>
  <arm_group>
    <arm_group_label>Study population</arm_group_label>
    <description>Patients subjects to a Guided Tissue Regeneration or Guided Bone Regeneration procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Guided Tissue Regeneration</intervention_name>
    <description>Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.
Covering alveolar bone defects after tooth-teeth extraction.</description>
    <arm_group_label>Study population</arm_group_label>
    <other_name>Guided Bone Regeneration</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The group will be selected in the entire population of the dental care center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged from 18 to 70

          -  Periodontal defects (e.g. cyst, bone tumour, crest augmentation...)

          -  Aleveolar bone defect after tooth (teeth) extraction

          -  Non opposition form (consent of the patient)

          -  Patients affiliated to the French social security

          -  Patients not under guardianship or judicial protection

        Exclusion Criteria:

          -  Pregnancy of breastfeeding women

          -  Severe smoker (&gt;10 cigarettes per day)

          -  Acute infections

          -  Allergies to the material (if an allergy of any kind is suspected, adequate exams must
             be carried out in advance)

          -  Refusal of the patient to adhere to surgical follow-up and to the limit in activity
             level

          -  Fever and/or local inflammation

          -  HIV positive known

          -  History of uncontrolled diabetes (untreated or not stabilized by treatment)

          -  History of treatments for previous corticosteroids, long-term (more than 6 months) and
             interrupted for less than 3 months

          -  History of chemotherapy in progress or during the last three months

          -  History of cervico-facial radiotherapy

          -  History of bone disease with disorders of blood circulation which is defined as
             Akbers-Schönberg disease or Paget's disease

          -  Known severe hyperparathyroïdism

          -  History of severe immune deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saïd Kimakhe, PhD, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalo-Universitaire de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saïd Kimakhe, Phd, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cabinet privé</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy Daculsi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Biomatlante</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura PAGNUCCO</last_name>
    <phone>0228020009</phone>
    <email>laurapagnucco@biomatlante.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nancy TRICHEREAU</last_name>
    <phone>0228020009</phone>
    <email>nancytrichereau@biomatlante.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de soins dentaires - Centre Hospitalo-Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Cheraud</last_name>
      <phone>0240087383</phone>
      <email>Marjorie.CHERAUDCARPENTIER@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Saïd KIMAKHE, PhD, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Badran ZAHI, PhD, DDS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe LESCLOUS, PhD, DDS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier STRUILLOU, PhD, DDS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet privé du Dr. S. Kimakhe</name>
      <address>
        <city>Nantes</city>
        <zip>44200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saïd KIMAKHE, PhD, DDS</last_name>
      <phone>0240897023</phone>
      <email>s.kimakhe@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Saïd KIMAKHE, PhD, DDS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Periodontal defects</keyword>
  <keyword>Alveolar bone preservation</keyword>
  <keyword>Collagen membrane</keyword>
  <keyword>Mucosa healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alveolar Bone Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03978962/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

